Aptadel Therapeutics — Pre-Series A · €2M

Aptadel closed a €2M bridge (pre-Series A) round. The Japanese investor group Newsight Tech Angels joined as a new investor, and the Little Warrior Foundation, already a shareholder, put in more capital. The money moves its Ewing sarcoma candidate ADEL-101 towards the clinic, and the company is now preparing a €9M Series A. In 2025 it also received a €450,000 non-dilutive AECC IMPACTO grant from the Spanish Association Against Cancer (AECC).